Reciprocal Regulation among miR-181d/CRY2/FBXL3/c-myc Signaling Axis Modulates Metabolism in Colorectal Cancer by Xiaofeng Guo, Xuehui Hong
RNA & DISEASE 2019; 6: e1613. doi: 10.14800/rd.1613; © 2019 by Xiaofeng Guo, et al. 
http://www.smartscitech.com/index.php/rd 
Page 1 of 4 
Reciprocal regulation among miR-181d/CRY2/FBXL3/c-myc 
signaling axis modulates metabolism in colorectal cancer 
Xiaofeng Guo1, Xuehui Hong1,2,3 
1Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China 
2Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian, China 
3Xiamen Municipal Key Laboratory of Gastrointestinal Oncology, Xiamen, Fujian, China
Correspondence: Xuehui Hong 
E-mail: hongxu28@vip.sina.com or hongxu@xmu.edu.cn
Received: October 13, 2018
Published: November 28, 2019
Patients with CRC (colorectal cancer) usually have a poor prognosis and the cure rate of CRC remained 
unsatisfied due to unfavorable curative effect. It is well known that microRNAs (miRNAs) and energy 
metabolism have pivotal roles in CRC progression. In a recent article in Cell Death & Disease by Xiaofeng Guo. 
et al. 2017, we have reported an oncogenic role of miR-181d in CRC by promoting glycolysis, and its underlying 
molecular mechanism about a new feedback loop among miR-181d/CRY2/FBXL3/c-myc signaling axis. Among 
these, we have identified the level of miR-181d was upregulated in CRC and the inhibition of miR-181d 
decreased glycolysis in CRC cells. We also found that c-myc played a central role in regulating cell glycolysis, 
which is required for the metabolic shift induced by miR-181d. Besides, we have demonstrated FBXL3 and 
CRY2 were direct targets of miR-181d and c-myc promoted miR-181d upregulation while inhibiting the 
expression of CRY2 and FBXL3 in CRC cells. The data from our recent article strongly suggest a new light onto 
the oncogenic function of the miR-181d in CRC. Furthermore, these findings represent a novel potential 
approach for silencing miR-181d/c-myc signaling pathway in CRC treatment. 
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Colorectal cancer (CRC) is the third most commonly 
diagnosed malignancy and the fourth leading cause of cancer 
death in the world with characteristics of fast progression, 
unfavorable curative effect, and poor prognosis [1]. According 
to newly published “Cancer Statistics, 2017” of United States, 
the estimated new CRC cases were 135,430, and the new 
deaths were 50,260 in 2017 [2]. In the past two decades, 
significant advances have been made in our understanding of 
CRC. Nonetheless, the cure rate of CRC remains insufficient 
and approximately 30%–50% of patients who undergo 
curative resection subsequently experience local and systemic 
recurrence, and the prognosis of patients with liver metastasis 
is still poor [3, 4]. Therefore, it was urged to make further 
exploration and search new targeted therapeutic approaches to 
get its morbidity and mortality under control [5]. 
In the past few decades, investigators have devoted 
considerable efforts to explore the etiology and pathogenesis 
of CRC [6]. CRC has variable genetic signatures, which can be 
as unique as the individual host, and it develops through at 
least 3 major pathways, which include chromosomal 
instability, mismatch repair, and methylate phenotype [7]. 
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However, the majority of recent studies have shown that in 
cancer cells the alterations of glucose metabolism are associ-
ated with miRNA dysregulation [8, 9] Reprogrammed energy 
metabolism to fuel rapid cell growth and proliferation is an 
emerging hallmark of cancer. Altered glucose metabolism in 
cancer cells is termed as ‘Warburg effect’, which describes the 
propensity of most cancer cells to take up glucose avidly and 
convert it primarily to lactate, despite available oxygen [10, 11]. 
The Warburg effect has been observed in many tumor types 
[12]. Recently progress had been made regarding the 
mechanistic understanding of glucose metabolism and 
associated diagnostic and therapeutic methods, which have 
been investigated in colorectal cancer. 
Large studies suggest that miRNA is involved in the 
development of CRC and plays important roles in multiple 
biological processes of CRC, such as cell growth, 
development, differentiation, survival, etc. [13-15]. Moreover, 
miRNAs have been shown to be involved in tumorigenesis 
where they function as tumor suppressors or oncomiRs. In 
addition, miRNAs participate in cell metabolism by regulating 
the expression of genes whose protein products either directly 
regulate metabolic machinery or indirectly modulate the 
expression of metabolic enzymes, serving as master regulators 
[16-18]. For example, miR-26a regulates glucose metabolism of 
CRC cells by directly targeting the pyruvate dehydrogenase 
complex component X (PDHX), which inhibits the 
conversion of pyruvate to acetyl coenzyme A in the citric acid 
cycle [19]. Furthermore, some miRNAs have been identified as 
diagnostic indicators, novel therapeutic targets in CRC. 
Therefore, identifying therapeutic miRNAs would be of great 
clinical value. 
As here highlighted, we have recently reported for the first 
time that miR-181d served as a critical oncogene, which 
played an important role in the metabolism of CRC [5]. The 
miR-181family includes 4 members, miR-181a, miR-181b, 
miR-181c and miR-181d. MiR-181a and miR-181b are 
transcribed from two separated gene loci 
(miR-181a-1/miR-181b-1 and miR-181a-2/ miR-181b-2). 
MiR-181c and miR-181d are transcribed from another locus 
[20]. Interestingly, effects of miR-181 family members on 
tumors are totally divergent. For example, miR-181a/b was 
reported to be dysregulated, and acted as either an oncogene 
or a tumor-suppressor gene via affecting metabolic shift [21]. In 
our study we found that miR-181d was significantly 
upregulated in human CRC tissues, cell lines and mouse 
models compared with their controls. In addition, our 
clinicopathological assays showed that miR-181d 
dysregulation was associated with CRC metastasis and TNM 
stage. Functionally, we found that high expression of 
miR-181d can promote cell proliferation, migration, and 
invasion, strongly suggesting that miR-181d was a prognostic 
indicator of CRC cell growth and metastasis and acts as an 
oncomiR in CRC. We also found that miR-181d was essential 
for CRC cell glycolysis. The inhibition of miR-181d by 
siRNA significantly decreased the level of the glycolysis 
under basal conditions, the glycolytic capacity, and the 
glycolytic reserve. In conclusion, Our study was the first to 
show that miR-181d exerted its oncogenic roles by promoting 
the Warburg effect. 
It has also become clear that the multifaceted oncogene, 
c-myc, plays an important regulatory role in glucose
metabolism [22, 23]. The c-myc protein functions as a
helix-loop-helix transcription factor and is a key regulator of
cell proliferation and cell fate decision [24]. To explore whether
other factors are critical for the inhibition of miR-181d
decreases glycolysis in CRC cells. We investigated the
expression of c-myc, hypoxia inducible factors α (HIF1α), and
PKM2 after miR-181d overexpression and showed that only
c-myc increased, which strongly indicated that c-myc was
required for the metabolic shift induced by miR-181d. On the
other hand, anti-miR-181d, 10058-F4, or FX11, the inhibitor
of miR-181d, c-myc and LDHA, significantly inhibited the
process of glycolysis observed in miR-181d-overexpressing
cells. Therefore, we suggested that upregulation of miR-181d
in CRC promoted glycolysis, which may be mediated by
c-myc and responsible for aggressiveness of CRC cells.
Although c-myc mediates the effect of miR-181d on
glycolysis in CRC cells, c-myc is not a direct target of 
miR-181d. To further reveal the mechanism of 
miR-181d-induced glycolysis, we predicted potential direct 
target of miR-181d through three different algorithms. We 
identified CRY2 and FBXL3 as two direct targets of 
miR-181d based on the following evidence that (i) miR-181d 
overexpression significantly decreased CRY2 and FBXL3 
protein expression; (ii) CRY2 and FBXL3 and miR-181d 
expression levels were negatively correlated; and (iii) 
3′-UTR-luciferase reporter activities of both CRY2 and 
FBXL3 were suppressed by miR-181d overexpression. It is 
known from the literature that CRY2/FBXL3 is able to 
decrease the expression of c-myc via driving proteolytic 
turnover of T58-phosphorylated c-myc [25]. So, we concluded 
that miR-181d stabilized c-myc through downregulating 
CRY2/FBXL3.  
Next, we sought to further investigate the transcriptional 
regulation of miR-181d. Though software analysis, luciferase 
reporter assay and CHIP assay, we proved that c-myc bound 
the promoter of miR-181d and augmented its expression. 
Thus miR-181d forms a positive feedback loop with c-myc. 
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Interestingly, previous report showed that c-myc can form a 
complex with HDAC1 or HDAC3 and transcriptionally 
repress down-stream gene expression [26]. Thus, we performed 
a co-IP and demonstrated that c-myc and interacted with 
HDAC3 instead of HDAC1. Furthermore, CHIP-PCR 
revealed that c-myc/HDAC3 complex impaired the 
expression of CRY2/FBXL3 by binding their promoters, 
which indicated that c-myc can form a negative feedback with 
CRY2/FBXL3. 
In summary, our recent publication demonstrated for the 
first time a miR-181d/CRY2/FBXL3/c-myc reciprocal 
feedback loop linking overexpression of miR-181d and c-myc 
with CRY2/FBXL3 suppression in CRC glucose metabolism 
(Figure 1), thus emphasizing the oncogenic role of miR-181d 
in CRC. Our present findings represent a novel potential 
approach for silencing c-myc/miR-181d signaling pathway in 
CRC treatment. 
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